|
Age (years)
|
59.5 ± 8.6
|
56.3 ± 8.1
|
0.055
|
|
Men/Women (%)
|
40/23 (64/36)
|
32/15 (68/32)
|
0.616
|
|
Body mass index (kg/m2)
|
25.7 ± 3.2
|
25.0 ± 2.9
|
0.225
|
|
Duration of diabetes (years)
|
11.7 ± 7.1
|
14.2 ± 7.2
|
0.076
|
|
Systolic blood pressure (mmHg)
|
126.9 ± 16.8
|
127.5 ± 15.1
|
0.851
|
|
Diastolic blood pressure (mmHg)
|
77.3 ± 10.5
|
77.1 ± 8.8
|
0.894
|
|
Lipid profile (mg/dL)
| | | |
|
Total cholesterol
|
155.7 ± 30.8
|
156.6 ± 33.6
|
0.885
|
|
Triglyceride
|
116.4 ± 62.0
|
134.1 ± 61.1
|
0.139
|
|
HDL-C
|
49.1 ± 11.3
|
46.3 ± 10.0
|
0.176
|
|
LDL-C
|
87.4 ± 23.8
|
90.5 ± 29.4
|
0.551
|
|
C-peptide (ng/mL)
|
2.3 ± 1.1
|
2.0 ± 1.1
|
0.108
|
|
eGFR (ml/min/1.73 m2)
|
83.5 ± 21.5
|
89.4 ± 19.3
|
0.142
|
|
Use of insulin, n (%)
|
16 (25)
|
25 (53)
|
0.003
|
|
Use of oral anti-diabetic drug, n (%)
|
55 (87)
|
40 (85)
|
0.740
|
|
Metformin, n (%)
|
48 (76)
|
39 (83)
|
0.386
|
|
Sulfonylurea, n (%)
|
24 (38)
|
16 (34)
|
0.662
|
|
Thiazolidinedione, n (%)
|
9 (14)
|
0 (0)
|
0.014
|
|
Glinide, n (%)
|
5 (8)
|
2 (4)
|
0.434
|
|
DPP 4 inhibitor, n (%)
|
22 (35)
|
17 (44)
|
0.892
|
|
α-glucosidase inhibitor, n (%)
|
15 (24)
|
9 (19)
|
0.558
|
|
Use of lipid-lowering agents, n (%)
|
46 (73)
|
36 (77)
|
0.670
|
|
Use of anti-hypertensive therapy, n (%)
|
47 (75)
|
32 (68)
|
0.452
|
|
ACE inhibitor or ARB, n (%)
|
51 (68)
|
25 (71)
|
0.717
|
|
CCB, n (%)
|
17 (27)
|
8 (17)
|
0.217
|
|
Thiazide, n (%)
|
6 (9.5)
|
6 (12.8)
|
0.589
|
|
Beta-blocker, n (%)
|
9 (14)
|
6 (12)
|
0.818
|
|
Use of aspirin, n (%)
|
32 (51)
|
22 (47)
|
0.679
|
|
Smoking (ex- or current smoker), n (%)
|
23 (37)
|
17 (36)
|
0.971
|
